Literature DB >> 24177177

Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.

Anne Schroeder1, Andreas Herrmann, Gregory Cherryholmes, Claudia Kowolik, Ralf Buettner, Sumanta Pal, Hua Yu, Gerhard Müller-Newen, Richard Jove.   

Abstract

Androgen receptor (AR) signaling is important for prostate cancer progression. However, androgen-deprivation and/or AR targeting-based therapies often lead to resistance. Here, we demonstrate that loss of AR expression results in STAT3 activation in prostate cancer cells. AR downregulation further leads to development of prostate cancer stem-like cells (CSC), which requires STAT3. In human prostate tumor tissues, elevated cancer stem-like cell markers coincide with those cells exhibiting high STAT3 activity and low AR expression. AR downregulation-induced STAT3 activation is mediated through increased interleukin (IL)-6 expression. Treating mice with soluble IL-6 receptor fusion protein or silencing STAT3 in tumor cells significantly reduced prostate tumor growth and CSCs. Together, these findings indicate an opposing role of AR and STAT3 in prostate CSC development. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24177177      PMCID: PMC4539262          DOI: 10.1158/0008-5472.CAN-13-0594

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.

Authors:  H L Adler; M A McCurdy; M W Kattan; T L Timme; P T Scardino; T C Thompson
Journal:  J Urol       Date:  1999-01       Impact factor: 7.450

2.  Prospective identification of tumorigenic prostate cancer stem cells.

Authors:  Anne T Collins; Paul A Berry; Catherine Hyde; Michael J Stower; Norman J Maitland
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  Essential role of STAT3 for embryonic stem cell pluripotency.

Authors:  R Raz; C K Lee; L A Cannizzaro; P d'Eustachio; D E Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients.

Authors:  S Akimoto; A Okumura; H Fuse
Journal:  Endocr J       Date:  1998-04       Impact factor: 2.349

Review 5.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

6.  Development of an IL-6 inhibitor based on the functional analysis of murine IL-6Ralpha(1).

Authors:  Monique Y Wiesinger; Serge Haan; Stefan Wüller; Maria-Elisabeth Kauffmann; Tobias Recker; Andrea Küster; Peter C Heinrich; Gerhard Müller-Newen
Journal:  Chem Biol       Date:  2009-07-31

Review 7.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

Review 8.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 9.  Control of senescence by CXCR2 and its ligands.

Authors:  Juan C Acosta; Ana O'Loghlen; Ana Banito; Selina Raguz; Jesús Gil
Journal:  Cell Cycle       Date:  2008-10-13       Impact factor: 4.534

10.  Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells.

Authors:  Rebecka Hellsten; Martin Johansson; Anna Dahlman; Olov Sterner; Anders Bjartell
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

View more
  94 in total

1.  STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth.

Authors:  Chunyan Zhang; Chanyu Yue; Andreas Herrmann; Jieun Song; Colt Egelston; Tianyi Wang; Zhifang Zhang; Wenzhao Li; Heehyoung Lee; Maryam Aftabizadeh; Yi Jia Li; Peter P Lee; Stephen Forman; George Somlo; Peiguo Chu; Laura Kruper; Joanne Mortimer; Dave S B Hoon; Wendong Huang; Saul Priceman; Hua Yu
Journal:  Cell Metab       Date:  2019-11-21       Impact factor: 27.287

2.  Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.

Authors:  Matthew I Confeld; Babak Mamnoon; Li Feng; Heather Jensen-Smith; Priyanka Ray; James Froberg; Jiha Kim; Michael A Hollingsworth; Mohiuddin Quadir; Yongki Choi; Sanku Mallik
Journal:  Mol Pharm       Date:  2020-07-22       Impact factor: 4.939

3.  Gene networks in basal cell carcinoma of the eyelid, analyzed using gene expression profiling.

Authors:  Tatsuya Yunoki; Yoshiaki Tabuchi; Tetsushi Hirano; Shigeharu Miwa; Johji Imura; Atsushi Hayashi
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

Review 4.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

5.  SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells.

Authors:  Hao Yu; Yudong Liu; Braden C McFarland; Jessy S Deshane; Douglas R Hurst; Selvarangan Ponnazhagan; Etty N Benveniste; Hongwei Qin
Journal:  Cancer Immunol Res       Date:  2015-02-03       Impact factor: 11.151

Review 6.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

7.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

Review 8.  Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Dean G Tang; Anna Dubrovska
Journal:  Stem Cells       Date:  2018-08-27       Impact factor: 6.277

Review 9.  Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.

Authors:  Qu Deng; Dean G Tang
Journal:  Endocr Relat Cancer       Date:  2015-08-18       Impact factor: 5.678

10.  EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumor-initiating cells through attenuation of STAT3 activation.

Authors:  Chien-Hung Lin; Li-Keng Chao; Peir-Haur Hung; Yann-Jang Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.